Esketamine - Johnson & Johnson

Drug Profile

Esketamine - Johnson & Johnson

Alternative Names: JNJ-54135419; S-ketamine

Latest Information Update: 10 Nov 2016

Price : $50

At a glance

  • Originator Johnson & Johnson
  • Class Analgesics; Antidepressants; Chlorobenzenes; Cyclohexanones; General anaesthetics; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Major depressive disorder
  • New Molecular Entity No

Highest Development Phases

  • Phase III Major depressive disorder

Most Recent Events

  • 01 Oct 2016 Janssen initiates enrolment in the phase I DriveSaFe2 trial for Major depressive disorder in Netherlands (Intranasal) (NCT02919579)
  • 28 Sep 2016 Janssen Research & Development plans the phase I DriveSaFe2 trial for Major depressive disorder in Netherlands (Intranasal) (NCT02919579)
  • 27 Sep 2016 Janssen Pharmaceutical plans a phase II trial for Major depressive disorder (Adjunctive treatment, Treatment-resistant) in Japan (Intranasal) (NCT02918318)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top